These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 37686586)
21. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195 [TBL] [Abstract][Full Text] [Related]
22. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Gargett T; Brown MP Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334 [TBL] [Abstract][Full Text] [Related]
23. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283 [TBL] [Abstract][Full Text] [Related]
25. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells. Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809 [TBL] [Abstract][Full Text] [Related]
26. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E Front Immunol; 2019; 10():3123. PubMed ID: 32117200 [TBL] [Abstract][Full Text] [Related]
27. GD2-targeting therapy: a comparative analysis of approaches and promising directions. Philippova J; Shevchenko J; Sennikov S Front Immunol; 2024; 15():1371345. PubMed ID: 38558810 [TBL] [Abstract][Full Text] [Related]
29. Virus-free CRISPR knock-in of a chimeric antigen receptor into Shankar K; Zingler-Hoslet I; Shi L; Katta V; Russell BE; Tsai SQ; Capitini CM; Saha K bioRxiv; 2024 Feb; ():. PubMed ID: 38405747 [TBL] [Abstract][Full Text] [Related]
31. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies. Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H Front Immunol; 2022; 13():847008. PubMed ID: 35464442 [TBL] [Abstract][Full Text] [Related]
32. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536 [TBL] [Abstract][Full Text] [Related]
33. Single VHH-directed BCMA CAR-NK cells for multiple myeloma. Ren Q; Zu Y; Su H; Lu Q; Xiang B; Luo Y; Zhang J; Song Y Exp Hematol Oncol; 2023 Nov; 12(1):98. PubMed ID: 38012722 [TBL] [Abstract][Full Text] [Related]
34. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma. Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720 [TBL] [Abstract][Full Text] [Related]
36. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro. Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J Cancer Manag Res; 2020; 12():3247-3255. PubMed ID: 32440221 [TBL] [Abstract][Full Text] [Related]
37. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Kailayangiri S; Altvater B; Spurny C; Jamitzky S; Schelhaas S; Jacobs AH; Wiek C; Roellecke K; Hanenberg H; Hartmann W; Wiendl H; Pankratz S; Meltzer J; Farwick N; Greune L; Fluegge M; Rossig C Oncoimmunology; 2017; 6(1):e1250050. PubMed ID: 28197367 [TBL] [Abstract][Full Text] [Related]